Brain disorders (Amsterdam, Netherlands)最新文献

{"title":"GLP-1 receptor agonists in diabetes-associated neurological disorders","authors":"Rokhsana Rasooli,&nbsp;Mohammad Sharifzadeh,&nbsp;Ali Rassouli,&nbsp;Saeed Aghebat Bekheir","doi":"10.1016/j.dscb.2026.100326","DOIUrl":"10.1016/j.dscb.2026.100326","url":null,"abstract":"<div><h3>Background/Objectives</h3><div>Diabetes is associated with complications in the central and peripheral nervous systems, including Parkinson’s disease, stroke, depression, epilepsy, diabetic peripheral neuropathy, and diabetic retinopathy. Evidence indicates that GLP-1 RAs may offer neuroprotective and systemic benefits beyond blood sugar regulation by affecting neuroinflammation, oxidative stress, mitochondrial issues, cell death, and synaptic plasticity. This review examines the effectiveness and potential of GLP-1 RAs in treating neurological comorbidities.</div></div><div><h3>Methods</h3><div>A thorough review of preclinical and clinical studies was performed to evaluate the impact of GLP-1 RAs on related neurological comorbidities.</div></div><div><h3>Results</h3><div>Preclinical studies show reduced loss of dopaminergic neurons, recovery of striatal dopamine levels, increased neurogenesis, and reduced oxidative stress and neuroinflammation. Clinical trials report improvements in motor and non-motor symptoms with exenatide and liraglutide. These drugs lower the risk of ischaemic stroke through vasoprotection, anti-inflammatory effects, and modulation of cardiovascular risk. Responses in psychiatric conditions vary. Epilepsy models demonstrate reduced seizure severity and cognitive deficits. In diabetic peripheral neuropathy, improvements include better nerve conduction, reduced neuroinflammation, and increased neuronal survival. In diabetic retinopathy, a slight increase in the incidence of related complications is noted.</div></div><div><h3>Conclusion</h3><div>GLP-1 RAs appear safe and suitable for neurological conditions associated with diabetes, except for retinopathy, and confirming their benefits will require improved strategies, comparative research, and further trials across diverse populations.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"23 ","pages":"Article 100326"},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148935051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospects of the therapeutic approaches of ketogenic diet in epilepsy management","authors":"Anmar Al-Taie,&nbsp;Jouwana Elmasri","doi":"10.1016/j.dscb.2026.100325","DOIUrl":"10.1016/j.dscb.2026.100325","url":null,"abstract":"<div><div>The ketogenic diet (KD) is a low-carbohydrate, high-fat diet. For many patients with uncontrolled epilepsy, KD treatments provide a proven non-pharmacological therapy alternative. This is particularly relevant for children with particular epilepsy syndromes and metabolic abnormalities. The aim of this study was to provide a broad overview of the KD, covering the therapeutic effects, relevant mechanisms, and clinical evidence underlying the implementation of the KD in epilepsy management. The study found that KD efficacy is syndrome-specific and patient-dependent. This diet can lower seizure frequency and, in certain cases, can provide prolonged seizure control when antiseizure medication is no longer effective. Their usage in epilepsy disorders, such as infantile spasms, Dravet syndrome, Lennox-Gastaut syndrome, and other refractory epileptic encephalopathies is most well supported. Restrictive dietary adherence, gastrointestinal and metabolic side effects, nutritional inadequacies, the risk of dyslipidemia and nephrolithiasis, and the requirement for close multidisciplinary monitoring are some of the primary limitations with KD therapies. Therefore, rather than being a general therapeutic approach, KD treatments should be used under specialized supervision and taken into consideration as part of a tailored treatment strategy for drug-resistant epilepsy.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"23 ","pages":"Article 100325"},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148935050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sabinene improves memory in naive and scopolamine-induced amnesic mice by inhibiting neurotransmitter metabolic enzymes and attenuating oxidative stress","authors":"Benneth Ben-Azu ,&nbsp;Akhator J. Amenotie ,&nbsp;Daniel T. Esuku ,&nbsp;Bienose S. Chijioke ,&nbsp;Olusegun G. Adebayo ,&nbsp;Jackson E. Onuelu ,&nbsp;Miracle K. Nekabari ,&nbsp;Ewhre O. Lawrence ,&nbsp;Obukohwo M. Oyovwi","doi":"10.1016/j.dscb.2026.100320","DOIUrl":"10.1016/j.dscb.2026.100320","url":null,"abstract":"<div><div>Sabinene (SAB) is a monoterpene hydrocarbon found in various essential oils, known for its neuroprotective and antioxidant properties. However, its effect on cognitive functions remains unexplored. This study aimed to investigate the memory-enhancing and nootropic effects of SAB in mice. Herewith, groups 1 and 2 received normal saline; groups 3–5 were pretreated with SAB (5, 10, and 20 mg/kg) alone, while mice in group 6 received donepezil (DPZ) (1 mg/kg) orally. Additionally, mice in groups 2–6 were treated with scopolamine (3 mg/kg, i.p.) 30 min after each treatment with SAB, respectively, for 14 days. Behavioral tests, like novel-object recognition and Y-maze tests to evaluate cognitive function and motor activity, were employed. Biochemical assays were conducted to measure neurotransmitter levels, molybdenum-containing enzymes, oxidative stress, and nitrergic markers in the prefrontal cortex (PFC) and hippocampus. Treatments with SAB (5, 10, and 20 mg/kg) improved spatial and non-spatial working memory on cognitive tests but were associated with reduced motor reactivity. SAB improved glutathione and glutathione peroxidase levels in the PFC and hippocampus compared to scopolamine. SAB alone significantly increased glutathione and superoxide dismutase levels and reduced catalase, glutathione peroxidase, and acetylcholinesterase activities in the PFC and hippocampus, respectively. SAB reduced aldehyde oxidase and xanthine oxidase, while DPZ lowered sulphite oxidase in the PFC and hippocampus relative to the controls, respectively. This study suggests SAB improves cognitive performance and reverses scopolamine-induced memory decline by enhancing antioxidant systems, cholinergic transmission, and molybdenum-containing enzymes.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"22 ","pages":"Article 100320"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148186978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Childhood-onset neurodegeneration with ataxia, tremor, optic atrophy, and cognitive decline (CONATOC): An integrated clinical series with genetic analysis","authors":"Sara Al Douri ,&nbsp;Maria Kibaek ,&nbsp;Laurence Gauquelin ,&nbsp;Christina Fagerberg ,&nbsp;Khunsa Faiz ,&nbsp;Faten Al Douri ,&nbsp;Sophie Grapentine ,&nbsp;Arnaud Vanlander ,&nbsp;Morgan Fullerton ,&nbsp;Marica Bakovic","doi":"10.1016/j.dscb.2026.100321","DOIUrl":"10.1016/j.dscb.2026.100321","url":null,"abstract":"<div><div>CONATOC<img>Childhood-Onset Neurodegeneration with Ataxia, Tremor, Optic Atrophy, and Cognitive decline-is a newly identified neurodegenerative disorder linked to pathogenic variants in the <em>SLC44A1</em> gene, which encodes the choline transporter-like protein CTL1. This transporter is essential for choline uptake in the nervous system, and its deficiency leads to a spectrum of neurological symptoms. We integrate clinical, neuroimaging, functional, and genetic data from four patients to refine the phenotype and variant classification. We present two newly identified cases and updated clinical and imaging data on two previously reported patients. All patients exhibited features such as tremors, ataxia, dysarthria, and cerebellar atrophy. Two siblings carried homozygous c.1549del (p.Asp517fs) variant (pathogenic). A third patient carried homozygous c.36+2T&gt;C (splice-site) likely pathogenic variant. One patient harbored a single heterozygous c.1306A&gt;G (p.Ile436Val) variant (VUS) with markedly reduced choline (−99.4%) and ethanolamine (−44.7%) uptake in fibroblasts. MRI consistently showed bilateral periventricular/deep white-matter T2/FLAIR hyperintensities with variable cerebellar atrophy and putaminal/substantia nigra susceptibility. Our series broadens the clinical–genetic spectrum of CONATOC and supports loss of CTL1 function as a convergent mechanism. Standardized iron-sensitive imaging and prospective outcome measures are needed to guide therapy development.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"22 ","pages":"Article 100321"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148242245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cerebrospinal fluid biomarkers for the subtle differentiation of neurodegenerative diseases and psychiatric disorders: A systematic review with network meta-analysis","authors":"Xuan Yang ,&nbsp;Lan Lei ,&nbsp;Ya-Ting Wang ,&nbsp;Si-Tong Feng ,&nbsp;Bin Chen ,&nbsp;Yi Zhang","doi":"10.1016/j.dscb.2026.100319","DOIUrl":"10.1016/j.dscb.2026.100319","url":null,"abstract":"<div><div>Cerebrospinal fluid (CSF) biomarkers are used to identify or detect the condition of multiple neurodegenerative diseases, even psychiatric disorders. However, discordant results between observational studies failed to meet the expectations of identifying neurodegenerative diseases and psychiatric disorders. We conducted this systematic review and network meta-analyses to investigate the CSF biomarkers in neurodegenerative diseases and psychiatric disorders, which contribute to the diagnosis of these diseases. Studies before September 2023 were searched based on databases. We included observational studies that compared the CSF levels of these biomarkers (Aβ_1–​₄₂, tau, p-tau_181, and α-synuclein) between healthy controls, neurodegenerative diseases, and psychiatric disorders. We conducted traditional pairwise analysis and network meta-analysis to evaluate the evidence concerning these CSF biomarkers between these neurodegenerative diseases and psychiatric disorders. This network meta-analysis included 117 studies with 25,210 patients to investigate the CSF biomarkers in multiple neurodegenerative diseases and psychiatric disorders (primarily depression, bipolar disorder, and schizophrenia). For CSF Aβ_1–​₄₂ levels, there were no statistically significant differences between these groups in network analysis. Regarding CSF t-tau and p-tau₁₈₁ levels, statistical significance was observed in comparing Alzheimer’s disease (AD) and other diseases, <em>e.g.</em>, amyotrophic lateral sclerosis (ALS). Regarding CSF α-synuclein levels, statistical significance was observed in several comparisons, <em>e.g.</em>, AD <em>vs.</em> ALS. Conclusively, we identified that CSF Aβ_1–​₄₂, t-tau, and p-tau₁₈₁ might be promising markers distinguishing AD from other neurodegenerative diseases and cognitive impairment. It is conflicting that CSF α-synuclein acts as a marker for diagnosing neurodegenerative diseases and predicts the presence of psychiatric disorders.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"22 ","pages":"Article 100319"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148186979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ionizing radiation acutely stimulates iron accumulation in the olfactory bulb","authors":"S. Kalteh ,&nbsp;N.R. Kamau ,&nbsp;L. Li ,&nbsp;E. Axelson ,&nbsp;C.Y. Lee ,&nbsp;V.A. Magnotta ,&nbsp;J.M. Buatti ,&nbsp;M.S. Petronek","doi":"10.1016/j.dscb.2026.100314","DOIUrl":"10.1016/j.dscb.2026.100314","url":null,"abstract":"<div><div>Radiation therapy leads to structural and functional changes in the brain resulting in a time-dependent cognitive decline. There are limited options to ameliorate this side-effect of therapy that significantly impacts patient quality of life; thus, a more robust understanding of the radiation injury pathogenesis is required. A commonly reported acute effect of cranial irradiation is the disruption of olfactory function, an effect that is also commonly seen in a variety of neurodegenerative processes (<em>e.g.,</em> Parkinson’s Disease). Iron accumulation has been demonstrated in neurodegenerative processes and can acutely affect olfactory function; thus, we hypothesized that cranial irradiation induces acute iron accumulation in the olfactory bulb of mice. Following 12 Gy of whole brain irradiation, a significant acute increase in iron was observed in the olfactory bulb as compared to the rest of the brain which corresponds with decreased olfactory function. Moreover, the use of T2* MRI as a surrogate marker of iron accumulation revealed significant loss in T2* signal in the glomerular cell layer of the olfactory bulb that corresponded with subsequent volume loss. These results suggest that the olfactory bulb is particularly sensitive to ionizing radiation induced iron accumulation with the glomerular cell layer being a potential key vulnerability.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"21 ","pages":"Article 100314"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147421378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spinal cord compression secondary to spinal extradural myeloid sarcoma in acute myeloid leukaemia: A case report and literature review","authors":"Prakash Palave ,&nbsp;Nitin Naikwade ,&nbsp;Ashvini Mahamuni ,&nbsp;Egemen Gok ,&nbsp;Kivanc Yangi ,&nbsp;Ismail Bozkurt ,&nbsp;Bipin Chaurasia","doi":"10.1016/j.dscb.2025.100303","DOIUrl":"10.1016/j.dscb.2025.100303","url":null,"abstract":"<div><h3>Introduction</h3><div>Myeloid sarcoma (MS) is a rare pathology that includes immature myeloid progenitor cells and is an infrequent form of acute myeloid leukemia (AML). It may occur de novo or be associated with other myeloproliferative disorders. Spinal involvement is rare but has the potential to result in catastrophic neurological consequences if not diagnosed promptly. Here, we present a young patient initially diagnosed with myelofibrosis whose disease evolved to AML and then thoracic extradural MS and acute spinal cord compression.</div></div><div><h3>Case presentation</h3><div>A 27-year-old woman came with paraparesis and worsening upper back pain. MRI demonstrated an extradural mass in the thoracic spine, causing compression of the spinal cord. Urgent decompressive laminectomy and subtotal resection were performed. Histopathology was positive for myeloid precursor cell sheets with myeloperoxidase, CD68, and CD43, which diagnosed MS. Postoperative course was uneventful, and adjuvant chemotherapy was initiated in her.</div></div><div><h3>Conclusion</h3><div>Thoracic spinal MS represents a diagnostic and therapeutic emergency that may arise during leukemic transformation of chronic myeloproliferative neoplasms such as myelofibrosis. Early radiologic evaluation, tissue diagnosis, and immediate surgical decompression are crucial for achieving optimal neurological outcomes. This case highlights maintaining a high suspicion of spinal MS in patients with evolving myeloid diseases since early multimodal treatment can avoid permanent neurological damage and may improve survival.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"21 ","pages":"Article 100303"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145685136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Main diagnoses and short-term disposition in a rapid-access neurology clinic: A 12-month service evaluation in a tertiary center in Argentina","authors":"Juan Antonio Pozo Putalivo,&nbsp;Martín Grecco,&nbsp;Guillermo Pablo Povedano","doi":"10.1016/j.dscb.2026.100313","DOIUrl":"10.1016/j.dscb.2026.100313","url":null,"abstract":"<div><h3>Background</h3><div>Rapid-access neurology (“hot clinic”) pathways provide timely specialist assessment for urgent neurological complaints. Evidence from middle-income settings remains scarce.</div></div><div><h3>Methods</h3><div>We conducted a 12-month retrospective evaluation of consecutive referrals to a rapid-access neurology pathway (target: 24–48 h) at a tertiary center in Buenos Aires, Argentina (June 2022–May 2023). We described referral reasons, final main diagnoses grouped into predefined syndromic categories, non-neurological presentations, and short-term disposition (admission vs. discharge). Multivariable logistic and modified Poisson regression estimated adjusted odds ratios (aORs) and risk ratios (aRRs) for admission and neurological vs. non-neurological presentations, adjusting for age, sex, referral source, and syndromic category.</div></div><div><h3>Results</h3><div>Among 1,714 visits (mean age 55.2 years; 58.9% women), 69.1% originated from the emergency department (ED). Overall, 83.0% involved a neurological condition, with leading syndromic diagnoses including headache/facial pain (35.4%), peripheral neuropathies (8.5%), and cognitive syndromes (4.5%). Non-neurological presentations accounted for 13.2%, mainly benign paroxysmal positional vertigo and syncope/collapse. One-quarter (25.3%) were referrals to explain prior tests. Admission rate was 7.4%, chiefly for vascular syndromes, headache, and delirium. Adjusted models showed ED referral increased admission risk (aRR 1.47, 95% CI 1.00–2.17) and neurological diagnosis likelihood (aRR 1.63, 95% CI 1.18–2.26), while test-explanation referrals reduced admission risk (aRR 0.21, 95% CI 0.06–0.62).</div></div><div><h3>Conclusions</h3><div>In a middle-income tertiary setting, this rapid-access neurology pathway managed mostly neurological presentations with low admission rates, but substantial activity stemmed from nonselective testing and non-neurological issues. Standardized criteria, training, and imaging stewardship could enhance access for urgent cases and reduce unnecessary utilization.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"21 ","pages":"Article 100313"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147421369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guillain–Barré syndrome following dengue infection in an adult patient: a case report","authors":"Nikhat Shahla Afsar ,&nbsp;Sumaiya Farah Marisa ,&nbsp;Nishat Ali ,&nbsp;Md. Imrul Hasan ,&nbsp;Mohammad Mahfuzur Rahman ,&nbsp;Sayat Quayum Mohona ,&nbsp;Rayhan Uddin Ahmed ,&nbsp;Mehadi Hasan ,&nbsp;Anika Shahidullah ,&nbsp;Chowdhury Adnan Sami","doi":"10.1016/j.dscb.2026.100306","DOIUrl":"10.1016/j.dscb.2026.100306","url":null,"abstract":"<div><h3>Background</h3><div>Dengue fever is a viral disease that presents with a wide range of neurological features. Although less frequent, Guillain–Barré Syndrome (GBS) is a life-threatening, postinfectious neurological sequela.</div></div><div><h3>Case summary</h3><div>A 44-year-old Bangladeshi male presented with flaccid quadriplegia during the recovery phase of serologically confirmed dengue fever. Cerebrospinal fluid (CSF) analysis showed albuminocytologic dissociation. The patient was treated with intravenous immunoglobulin therapy and supportive measures, including mechanical ventilation. His condition improved after 14 days of critical care.</div></div><div><h3>Conclusion</h3><div>This case underscores the importance of maintaining a high index of suspicion for GBS in patients with dengue fever in endemic regions. Early diagnosis and multidisciplinary management are essential for better outcomes.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"21 ","pages":"Article 100306"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146022971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brain Disorders: Persistent paradoxes, renewed resolve","authors":"Kambiz N. Alavian","doi":"10.1016/j.dscb.2025.100302","DOIUrl":"10.1016/j.dscb.2025.100302","url":null,"abstract":"","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"21 ","pages":"Article 100302"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147538441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}